Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin

European Journal of Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 115427 - 115427

Published: April 1, 2025

The antibody-drug conjugate enfortumab vedotin (EV) received approval in patients with metastatic urothelial carcinoma (mUC). EV-related cutaneous toxicities are frequently reported, whether AEs association survival may exist is still unknown. We aim to report the between and receiving EV. This retrospective study enrolled treated monotherapy EV from two oncology centers, followed up for at least 3-months, data collection demographics, treatments, toxicities, outcomes. primary endpoint was progression-free (PFS) experiencing or not. Overall (OS) secondary endpoint. Data 63 July 19, 2019, March 12, 2024, were collected. Among them, 18 (28.6 %) any-grade during treatment showed significantly longer median PFS (mPFS: 9.2 vs. 4.7 months, hazard ratio [HR] 0.35; p = 0.0041) OS (mOS: not reached 8.4 HR 0.38; 0.0253). multivariate analysis a significant of improved (HR 0.40, 0.0319), did demonstrate even if tendency kept 0.41, 0.067). These results support that toxicity (skin rash) had prolonged PFS. With recent expansion combined using plus pembrolizumab first-line mUC patients, need be carefully monitored optimized dedicated management provided, considering predictive patient outcome.

Language: Английский

---

Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives

Journal of Personalized Medicine, Journal Year: 2023, Volume and Issue: 13(9), P. 1339 - 1339

Published: Aug. 30, 2023

Antibody–drug conjugates (ADCs) are complex chemical structures composed of a monoclonal antibody, serving as link to target cells, which is conjugated with potent cytotoxic drug (i.e., payload) through linker. Inspired by Paul Ehrlich’s concept the ideal anticancer “magic bullet”, ADCs also highly specific agents, they have been demonstrated recognize, bind, and neutralize cancer limiting injuries normal cells. among newest pharmacologic breakthroughs in treating solid hematologic malignancies. Indeed, recent years, various approved Food Drug Administration European Medicines Agency for treatment several cancers, resulting “practice-changing” approach. However, despite these successes, no ADC patients affected renal cell carcinoma (RCC). In present paper, we thoroughly reviewed current literature summarized preclinical studies clinical trials that evaluated activity toxicity profile RCC patients. Moreover, scrutinized potential causes that, until now, hampered therapeutical success those Finally, discussed novel strategies would improve development their efficacy

Language: Английский

---

Immunotherapy guided precision medicine in solid tumors

Advances in protein chemistry and structural biology, Journal Year: 2024, Volume and Issue: unknown, P. 249 - 292

Published: Jan. 1, 2024

Language: Английский

---

Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: Dec. 20, 2023

Urinary tumors primarily consist of kidney, urothelial, and prostate malignancies, which pose significant treatment challenges, particularly in advanced stages. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic approach, combining monoclonal antibody specificity with cytotoxic chemotherapeutic payloads. This review highlights recent advancements, opportunities, challenges ADC application for urinary tumors. We discuss the FDA-approved ADCs other novel under investigation, emphasizing their potential to improve patient outcomes. Furthermore, we explore strategies address such toxicity management, predictive biomarker identification, resistance mechanisms. Additionally, examine integration modalities, including immune checkpoint inhibitors, targeted therapies, radiation therapy. By addressing these exploring innovative approaches, development may significantly enhance options outcomes patients tumor.

Language: Английский

---

Transurethral resection of bladder tumor-based bladder preservation therapy for refractory high risk non-muscle invasive bladder cancer: Current landscape and future directions

Frontiers in Surgery, Journal Year: 2023, Volume and Issue: 10

Published: April 12, 2023

Bladder cancer is the most common malignant tumor of urinary system worldwide. Approximately 75% patients with bladder present non-muscle-invasive (NMIBC), which effectively managed transurethral resection (TURBT). For refractory high risk NMIBC, are typically treated by radical cystectomy (RC). TURBT deserves further evaluation. Growing evidence suggests that repeated TURBT-based bladder-sparing approaches may improve oncological outcomes and quality life in highly selected patients. Novel imaging techniques biomarkers aid selection postoperative surveillance. With growing interest adding immunotherapy to cancer, based enable preservation therapy for NMIBC. Here we summarize current landscape, surveillance, future directions applying therapy.

Language: Английский

---

Metastatic bladder cancer forming a sigmoidorectal fistula after enfortumab vedotin therapy: a case report

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: Nov. 9, 2023

We report the case of a 68-year-old man who developed sigmoidorectal fistula after marked response to enfortumab vedotin for advanced bladder cancer. The patient had undergone radical cystectomy with ileal conduit neoadjuvant chemotherapy. Six months surgery, local recurrence in pelvic cavity and multiple lung metastases were found, was administered pembrolizumab as second-line therapy. Due worsening suspected invasion sigmoid colon rectum, initiated third-line therapy comprehensive genomic profiling simultaneously performed. Enfortumab remarkably effective, disappeared, recurrent lesion shrank volume although found form through tumor cavity. Immunohistochemical analysis specimens exhibited increased nectin-4 expression. This rare metastatic cancer associated effective suggests that expression might be useful predicting treatment vedotin.

Language: Английский

---

Occult urothelial carcinoma with mediastinal metastasis: A case report

Oncology Letters, Journal Year: 2024, Volume and Issue: 27(4)

Published: Feb. 9, 2024

Occult urothelial carcinoma (UC), particularly with mediastinal metastases, is an uncommon clinical occurrence. The present study describes the unusual case of a 70‑year‑old male patient who developed metastases from occult UC. Histological evaluations and immunohistochemical features tumor were indicative UC; however, extensive imaging failed to identify primary urological lesion. findings suggest that UCs, despite their rarity, should be considered in cases where patients tumors exhibit chest‑related symptoms. Prompt pathological examinations are crucial for ascertaining nature origin tumor. Moreover, individualized treatment performed strict accordance established oncology guidelines.

Language: Английский

---

Deciphering riddles in molecular subtyping of bladder cancer

Asian journal of urology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

---